Trials / Unknown
UnknownNCT05198752
A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Stemirna Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoantigen mRNA Personalised Cancer SW1115C3 | Subcutaneous Injection |
Timeline
- Start date
- 2022-03-18
- Primary completion
- 2023-12-22
- Completion
- 2024-06-12
- First posted
- 2022-01-20
- Last updated
- 2022-10-17
Locations
3 sites across 2 countries: Australia, Austria
Source: ClinicalTrials.gov record NCT05198752. Inclusion in this directory is not an endorsement.